Prostate Cancer News

Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer (May 1, 2018)

CancerConnect News: There is an ongoing discussion about the optimal timing of using androgen deprivation therapy (ADT) in men with prostate cancer who have relapsed based on a rising prostate-specific antigen (PSA) and in men with early stage prostate... Continue Reading

Xtandi® A New Standard Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer? (February 22, 2018)

CancerConnect News:  Results from the Phase 3 PROSPER clinical trial in patients with non-metastatic Castration-Resistant Prostate Cancer (CRPC) were released this week at the 2018 Genitourinary Cancers Symposium in San Francisco and demonstrate that... Continue Reading

Erleada is The First Treatment for Non-metastatic Castration-resistant Prostate Cancer (February 19, 2018)

CancerConnect News:  Men who are being treated with androgen deprivation therapy (ADT) and see their prostate specific antigen (PSA) levels begin to increase have a new treatment option. The U.S. Food and Drug Administration (FDA) has approved Erleada... Continue Reading

Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation (February 14, 2018)

Myriad Genetics a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study will be featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, Calif. ... Continue Reading

Two Advances in Prostate Cancers You Might Not Know About (September 8, 2017)

Prostate cancer isn’t just about men, and it may be inherited. A recent study led by Peter Nelson, MD (Fred Hutchinson Cancer Research Center) has shown that 12% of advanced prostate cancers may be caused by 16 different heritable genes. That means... Continue Reading

Is Lynparza a Precision Cancer Medicine for Prostate Cancer? (July 12, 2017)

Scientists have developed a new three-in-one blood test that has the potential to turn Lynparza (olaparib) into a precision medicine for prostate cancer. Lynparza is a PARP inhibitor, a newer precision cancer medicine that blocks enzymes involved in repairing... Continue Reading

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival (June 7, 2017)

Adding Zytiga (abiraterone acetate) plus prednisone to standard hormonal therapy for men with newly diagnosed, metastatic prostate cancer lowers the chance of death by 38%, and more than doubled the median time until the cancer worsened, from 14.8 months... Continue Reading

Latest Prostate Cancer News By Stage


Early Stage I-II (A-B) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Early Stage I-II (A-B) Prostate Cancer

Locally Advanced Stage III (C) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Locally Advanced Stage III (C) Prostate Cancer

Metastatic Stage IV (D) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Metastatic Stage IV (D) Prostate Cancer

Refactory/Recurrent Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Refactory/Recurrent Prostate Cancer

Screening/Prevention Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Prostate Cancer